Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The AKT pathway is often activated in HCC cases, and a longer exposure to tyrosine kinase inhibitors such as sorafenib may lead to over-activation of the AKT pathway, leading to HCC resistance. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurma, Keerthi, Zeybek Kuyucu, Ayca, Roth, Gaël S., Sturm, Nathalie, Mercey-Ressejac, Marion, Abbadessa, Giovanni, Yu, Yi, Lerat, Herve, Marche, Patrice N., Decaens, Thomas, Macek Jilkova, Zuzana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784348/
https://www.ncbi.nlm.nih.gov/pubmed/36555845
http://dx.doi.org/10.3390/ijms232416206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784348/
https://www.ncbi.nlm.nih.gov/pubmed/36555845
http://dx.doi.org/10.3390/ijms232416206

Ejemplares similares